BNP Paribas Arbitrage SA boosted its position in shares of Cantel Medical Corp. (NYSE:CMD) by 60.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,758 shares of the company’s stock after purchasing an additional 7,055 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Cantel Medical Corp. were worth $1,766,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Cantel Medical Corp. during the 2nd quarter valued at $376,271,000. Vanguard Group Inc. bought a new stake in Cantel Medical Corp. during the 2nd quarter valued at $246,860,000. Neuberger Berman Group LLC bought a new stake in Cantel Medical Corp. during the 2nd quarter valued at $96,236,000. Dimensional Fund Advisors LP bought a new stake in Cantel Medical Corp. during the 2nd quarter valued at $75,756,000. Finally, Wells Fargo & Company MN bought a new stake in Cantel Medical Corp. during the 2nd quarter valued at $75,715,000. Institutional investors own 86.19% of the company’s stock.

Shares of Cantel Medical Corp. (NYSE CMD) opened at $106.10 on Friday. The company has a current ratio of 2.41, a quick ratio of 1.49 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $4,404.63, a price-to-earnings ratio of 50.49 and a beta of 1.23. Cantel Medical Corp. has a 52-week low of $69.21 and a 52-week high of $106.19.

Cantel Medical Corp. (NYSE:CMD) last announced its earnings results on Thursday, September 28th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.02. The business had revenue of $205.50 million for the quarter, compared to analysts’ expectations of $200.32 million. Cantel Medical Corp. had a return on equity of 17.60% and a net margin of 9.27%. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. equities research analysts forecast that Cantel Medical Corp. will post 2.34 earnings per share for the current fiscal year.

The business also recently announced a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Wednesday, January 17th will be given a dividend of $0.085 per share. This represents a yield of 0.17%. The ex-dividend date is Tuesday, January 16th. This is a boost from Cantel Medical Corp.’s previous Semi-Annual dividend of $0.07. Cantel Medical Corp.’s dividend payout ratio (DPR) is 8.19%.

Several analysts have issued reports on CMD shares. Sidoti raised Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 target price on the stock in a research report on Wednesday, August 2nd. Zacks Investment Research raised Cantel Medical Corp. from a “hold” rating to a “buy” rating and set a $83.00 target price on the stock in a research report on Tuesday, August 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cantel Medical Corp. in a research report on Friday, September 1st. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $91.67.

In other news, Chairman Charles M. Diker sold 20,500 shares of the firm’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $99.15, for a total value of $2,032,575.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark N. Diker sold 7,000 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $98.90, for a total value of $692,300.00. The disclosure for this sale can be found here. Insiders sold a total of 36,368 shares of company stock valued at $3,576,028 in the last three months. Insiders own 14.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “BNP Paribas Arbitrage SA Grows Holdings in Cantel Medical Corp. (CMD)” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/bnp-paribas-arbitrage-sa-grows-holdings-in-cantel-medical-corp-cmd/1725619.html.

Cantel Medical Corp. Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Want to see what other hedge funds are holding CMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cantel Medical Corp. (NYSE:CMD).

Institutional Ownership by Quarter for Cantel Medical Corp. (NYSE:CMD)

Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.